Premium
Topical imiquimod treatment of residual or recurrent cervical intraepithelial neoplasia lesions (TOPIC‐2): A randomised controlled trial
Author(s) -
Sande Anna J. M.,
Baars Romy,
Koeneman Margot M.,
Gerestein Cornelis G.,
Kruse ArnoldJan,
Esch Edith M. G.,
Vos van Steenwijk Peggy J.,
Muntinga Caroline L. P.,
Willemsen Sten P.,
Doorn Helena C.,
Kemenade Folkert J.,
Beekhuizen Helene J.
Publication year - 2025
Publication title -
bjog: an international journal of obstetrics and gynaecology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.157
H-Index - 164
eISSN - 1471-0528
pISSN - 1470-0328
DOI - 10.1111/1471-0528.17808
Subject(s) - imiquimod , medicine , cervical intraepithelial neoplasia , randomization , randomized controlled trial , surgery , gynecology , cervical cancer , dermatology , cancer
Abstract Objective To investigate the efficacy of imiquimod in women with residual or recurrent cervical intraepithelial neoplasia (rrCIN), compared with large loop excision of the transformation zone (LLETZ). Design Randomised controlled non‐inferiority trial. Setting One academic and one regional hospital in the Netherlands. Population Thirty‐five women with rrCIN were included in the study between May 2016 and May 2021. Methods Women were randomised to receive treatment with 5% imiquimod cream (12.5 mg) intravaginally (three times a week for a duration of 16 weeks) or a LLETZ procedure (standard treatment). Main outcome measures The primary outcome was reduction to normal cytology at 6 months after starting treatment. Secondary outcomes were clearance of high‐risk human papilloma virus (hr‐HPV) in both groups and reduction to ≤CIN1 in the imiquimod group. Side effects were monitored. Results Treatment success was 33% (6/18) in the imiquimod group versus 100% (16/16) in the LLETZ group ( P < 0.001), whereas HPV clearance was 22% (4/18) in the imiquimod group versus 88% (14/16) in the LLETZ group ( P < 0.001). After the randomisation of 35 women, the futility of treatment with imiquimod was proven and the trial was prematurely finished. In the follow‐up period, three patients remained without additional treatment, whereas all other patients underwent LLETZ, conisation or hysterectomy. In the LLETZ group none of the patients received additional treatment during 2 years of follow‐up. Conclusions This is the first randomised controlled trial to show that topical imiquimod has a significantly lower success rate in terms of reduction to normal cytology and hr‐HPV clearance, compared with LLETZ, in women with rrCIN. Additionally, imiquimod has numerous side effects and after using imiquimod most women with rrCIN still required additional surgical treatment.